Comparative analysis of assays to measure CAR T cell-mediated cytotoxicity

Genome engineering using the CRISPR-Cas9 system

Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133

Immune checkpoint inhibitors: recent progress and potential biomarkers

Darvin, P., Toor, S. M., Sasidharan Nair, V., & Elkord, E. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0191-1 · Cited by 2,035

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831

Analysis of apoptosis by propidium iodide staining and flow cytometry

Riccardi, C., & Nicoletti, I. (2006) · Nature Protocols · doi:10.1038/nprot.2006.238 · Cited by 1,685

Human chimeric antigen receptor macrophages for cancer immunotherapy

Klichinsky, M., Ruella, M., Shestova, O., Lu, X. M., Best, A., Zeeman, M., Schmierer, M., Gabrusiewicz, K., Anderson, N. R., Petty, N. E., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0462-y · Cited by 1,495

CRISPR-engineered T cells in patients with refractory cancer

Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., Mangan, P. A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020) · Science · doi:10.1126/science.aba7365 · Cited by 1,478

CD107a as a functional marker for the identification of natural killer cell activity

Alter, G., Malenfant, J., & Altfeld, M. A. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.08.008 · Cited by 1,416

Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs.

BRUNNER, K. T., Mauël, J., Cerottini, J. C., & Chapuis, B. (1968) · PubMed Central · Cited by 1,367

A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity

Decker, T., & Lohmann‐Matthes, M. (1988) · Journal of Immunological Methods · doi:10.1016/0022-1759(88)90310-9 · Cited by 1,366

Mass Cytometry: Single Cells, Many Features

Spitzer, M. H., & Nolan, G. P. (2016) · Cell · doi:10.1016/j.cell.2016.04.019 · Cited by 1,199

Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response

Wang, D., Wu, X., & Sun, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 538

Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy

Abou-el-Enein, M., Elsallab, M., Feldman, S. A., Fesnak, A. D., Heslop, H. E., Marks, P., Till, B. G., Bauer, G., & Savoldo, B. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0084 · Cited by 321

Deep generative models design mRNA sequences with enhanced translational capacity and stability

Zhang, H., Liu, H., Xu, Y., Huang, H., Liu, Y., Wang, J., Qin, Y., Wang, H., Ma, L., Xun, Z., et al. (2025) · Science · doi:10.1126/science.adr8470 · Cited by 98

Promises and challenges of a decentralized CAR T-cell manufacturing model

Shah, M., Krull, A., Odonnell, L., de Lima, M. J., & Bezerra, E. (2023) · Frontiers in Transplantation · doi:10.3389/frtra.2023.1238535 · Cited by 77

GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18

Glienke, W., Dragon, A. C., Zimmermann, K., Martyniszyn, A., Mertens, M., Abken, H., Rössig, C., Altvater, B., Aleksandrova, K., Arseniev, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.839783 · Cited by 79

Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives

Sršen, L., Janžič, L., Ihan, A., & Kopitar, A. N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1378944 · Cited by 76

An iPSC-derived exosome-pulsed dendritic cell vaccine boosts antitumor immunity in melanoma

Wang, R., Zhu, T., Hou, B., & Huang, X. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.06.005 · Cited by 66

Nattokinase-Mediated Regulation of Tumor Physical Microenvironment to Enhance Chemotherapy, Radiotherapy, and CAR-T Therapy of Solid Tumor

Zhang, Y., Pei, P., Zhou, H., Xie, Y., Yang, S., Shen, W., Hu, L. T., Zhang, Y., Liu, T., & Yang, K. (2023) · ACS Nano · doi:10.1021/acsnano.2c12463 · Cited by 62

Time to evolve: predicting engineered T cell-associated toxicity with next-generation models

Donnadieu, E., Luu, M., Alb, M., Anliker, B., Arcangeli, S., Bonini, C., Angelis, B. D., Choudhary, R., Espie, D., Galy, A. H. M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003486 · Cited by 66

Modulating tumor physical microenvironment for fueling CAR-T cell therapy

Luo, Z. Y., Yao, X., Li, M., Fang, D., Fei, Y., Cheng, Z., Xu, Y., & Zhu, B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114301 · Cited by 59

Development of Nectin4/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors

Li, F., Zhao, S., Cheng, W., Hu, Y., Xu, T., Xin, X., Zhu, T., Shang, L., Ke, S., Zhou, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.958082 · Cited by 62

Breaking‐Down Tumoral Physical Barrier by Remotely Unwrapping Metal‐Polyphenol‐Packaged Hyaluronidase for Optimizing Photothermal/Photodynamic Therapy‐Induced Immune Response

Sun, Q., Li, Y., Shen, W. H., Shang, W., Xu, Y., Yang, J., Chen, J., Gao, W., Wu, Q., Xu, F., et al. (2024) · Advanced Materials · doi:10.1002/adma.202310673 · Cited by 50

TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges

Golikova, E., Alshevskaya, A., Alrhmoun, S., Sivitskaya, N. A., & Sennikov, S. V. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05703-9 · Cited by 50

Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics

Kirouac, D. C., Zmurchok, C., & Morris, D. (2024) · npj Systems Biology and Applications · doi:10.1038/s41540-024-00355-3 · Cited by 39

Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?

Guedan, S., Luu, M., Ammar, D., Barbao, P., Bonini, C., Bousso, P., Buchholz, C. J., Casucci, M., Angelis, B. D., Donnadieu, E., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003487 · Cited by 38

Optimizing viral transduction in immune cell therapy manufacturing: key process design considerations

Liu, D., & Kang-Zheng, L. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06524-0 · Cited by 37

Biomaterials promote in vivo generation and immunotherapy of CAR-T cells

Qin, Y., Li, Y., He, X., Wang, X., Li, W., & Zhang, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1165576 · Cited by 35

Expanding CAR-T cell immunotherapy horizons through microfluidics

Kim, H., Kim, S., Lim, H., & Chung, A. J. (2024) · Lab on a Chip · doi:10.1039/d3lc00622k · Cited by 34

Bioengineered immunocompetent preclinical trial-on-chip tool enables screening of CAR T cell therapy for leukaemia

Ma, C., Wang, H., Liu, L., Chen, R., Mukherjee, N., Tong, J., Kazmi, S., Fang, X., Witkowski, M. T., Aifantis, I., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01428-2 · Cited by 35

Bioassay Development for Bispecific Antibodies—Challenges and Opportunities

Register, A. C., Tarighat, S. S., & Lee, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105350 · Cited by 32

Better by design: What to expect from novel CAR-engineered cell therapies?

Luginbuehl, V., Abraham, E., Kovar, K., Flaaten, R., & Müller, A. M. S. (2022) · Biotechnology Advances · doi:10.1016/j.biotechadv.2022.107917 · Cited by 29

Review of flow cytometry as a tool for cell and gene therapy

Lazarski, C. A., & Hanley, P. J. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2023.10.005 · Cited by 25

Evaluation of CAR-T cell cytotoxicity: Real-time impedance-based analysis

Lisby, A., Carlson, R. D., Baybutt, T. R., Weindorfer, M., & Snook, A. E. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2021.08.002 · Cited by 24

Characterizing the regulatory Fas (CD95) epitope critical for agonist antibody targeting and CAR-T bystander function in ovarian cancer

Mondal, T., Gaur, H., Wamba, B. E. N., Michalak, A. G., Stout, C., Watson, M. R., Aleixo, S. L., Singh, A. N., Condello, S., Faller, R., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01229-7 · Cited by 21

Modified pectin with anticancer activity in breast cancer: A systematic review

Garrido, G., Garrido‐Suárez, B. B., Mieres-Arancibia, M., Valdés, M., & Ardiles, A. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127692 · Cited by 21

Powering prescription: Mitochondria as “Living Drugs” – Definition, clinical applications, and industry advancements

Caicedo, A., Morales, E., Moyano, A., Peñaherrera, S., Peña-Cisneros, J., Benavides-Almeida, A., Pérez-Meza, Á. A., Haro-Vinueza, A., Ruiz, C., Robayo, P., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.107018 · Cited by 21

Model‐informed drug development of autologous CAR‐T cell therapy: Strategies to optimize CAR‐T cell exposure leveraging cell kinetic/dynamic modeling

Laughlin, A. M. M., Milligan, P. A., Yee, C., & Bergstrand, M. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13011 · Cited by 19

Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs)

Cassioli, C., Patrussi, L., Valitutti, S., & Baldari, C. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214255 · Cited by 20

Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials

Jonus, H. C., Burnham, R. E., Ho, A., Pilgrim, A. A., Shim, J., Doering, C. B., Spencer, H. T., & Goldsmith, K. C. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2057012 · Cited by 19

Mechanism of action, potency and efficacy: considerations for cell therapies

Simon, C. G., Bozenhardt, E. H., Celluzzi, C. M., Dobnik, D., Grant, M., Lakshmipathy, U., Nebel, T., Peltier, L., Ratcliffe, A., Sherley, J. L., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05179-7 · Cited by 18

Activation of cancer immunotherapy by nanomedicine

Wang, L., Xu, H., Weng, L., Sun, J., Jin, Y. H., & Xiao, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1041073 · Cited by 18

Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium

Marton, C., Clémenceau, B., Dachy, G., Demerle, C., Derenne, S., Ferrand, C., Giverne, C., Latouche, J.-B., Lemée, L., Martinet, J., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02637-8 · Cited by 16

Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with 89Zirconium oxine for PET imaging

Leland, P., Kumar, D., Nimmagadda, S., Bauer, S. R., Puri, R. K., & Joshi, B. H. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04142-2 · Cited by 17

Current advances in experimental and computational approaches to enhance CAR T cell manufacturing protocols and improve clinical efficacy

Colina, A. S., Shah, V., Shah, R. K., Kozlik, T., Dash, R. K., Terhune, S. S., & Zamora, A. E. (2024) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2024.1310002 · Cited by 12

Advancement and Challenges in Monitoring of CAR-T Cell Therapy: A Comprehensive Review of Parameters and Markers in Hematological Malignancies

Ploch, W., Sadowski, K. A., Olejarz, W., & Basak, G. W. (2024) · Cancers · doi:10.3390/cancers16193339 · Cited by 13

Non-viral vectors for chimeric antigen receptor immunotherapy

Tretbar, S., Rurik, J. G., Rustad, E. H., Sürün, D., Koehl, U., Olweus, J., Buchholz, F., Ivics, Z., Fricke, S., & Blache, U. (2024) · Nature Reviews Methods Primers · doi:10.1038/s43586-024-00348-w · Cited by 15

CAR‐T Cell Manufacturing for Hematological and Solid Tumors: From the Preclinical to Clinical Point of View

Capolla, S., Rasool, M., Toffoli, G., & Bo, M. D. (2025) · Cancer Medicine · doi:10.1002/cam4.70726 · Cited by 13

Dynamics of macrophage tumor infiltration

Adebowale, K., Guerriero, J. L., & Mitragotri, S. (2023) · Applied Physics Reviews · doi:10.1063/5.0160924 · Cited by 13

Hyaluronidase nanogel-armed CAR-T cell for synergistically reducing tumor extracellular matrix and improving efficacy against solid tumors

Zhao, H., Gao, Y., Ma, S., Si, X., Li, J., Qi, Y., Huang, Z., Zhang, Y., Sun, T., Li, L., et al. (2025) · Nano Research · doi:10.26599/nr.2025.94907359 · Cited by 12

In vitro CAR-T cell killing: validation of the potency assay

Piccinini, C., Carloni, S., Arienti, C., Pancisi, E., Fanini, F., Pignatta, S., Soldati, V., Stefanelli, M., Granato, A. M., Martinelli, G., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03753-y · Cited by 11

Analysis of the measurements used as potency tests for the 31 US FDA-approved cell therapy products

Simon, C. G., Bozenhardt, E. H., Celluzzi, C. M., Dobnik, D., Grant, M., Lakshmipathy, U., Nebel, T., Peltier, L., Ratcliffe, A., Sherley, J. L., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06253-4 · Cited by 11

A dual-luciferase bioluminescence system for the assessment of cellular therapies

Chavez, A. G. T., McKenna, M. K., Balasubramanian, K., Riffle, L. A., Patel, N. L., Kalen, J. D., Croix, B. S., Leen, A. M., & Bajgain, P. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200763 · Cited by 10

Applications and evolution of 3D cancer-immune cell models

Co, I. L., Fomina, A., Nurse, M., & McGuigan, A. P. (2024) · Trends in biotechnology · doi:10.1016/j.tibtech.2024.06.008 · Cited by 10

In vitro evaluation of CAR-T cells in patient-derived glioblastoma models

Brakel, B. A., Chokshi, C., Salim, S. K., Venugopal, C., & Singh, S. K. (2021) · STAR Protocols · doi:10.1016/j.xpro.2021.100920 · Cited by 10

Biophysical phenotyping of single-cell based on impedance and application for individualized precision medicine

Chen, S., Zhang, S., & Zhu, R. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.116410 · Cited by 10

Quality assessment strategy development and analytical method selection of GMP grade biological drugs for gene and cell therapy

Yang, Q., Lee, N., Johnson, N., Hong, J., Zhao, J. Q., Sun, X., & Zhang, J. (2025) · BBA Advances · doi:10.1016/j.bbadva.2025.100151 · Cited by 9

Cell trajectory modulation: rapid microfluidic biophysical profiling of CAR T cell functional phenotypes

Zeming, K. K., Quek, K. Y., Sin, W., Teo, D. B. L., Cheung, K., Goh, C. R., Kairi, F., Lee, E., Lim, F., Seng, M. S.-F., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59789-w · Cited by 9

Steps toward nebulization in-use studies to understand the stability of new biological entities

Montefusco-Pereira, C. V. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103461 · Cited by 9

Bringing function to the forefront of cell therapy: how do we demonstrate potency?

Lowdell, M. W., & Weil, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1226841 · Cited by 9

Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T Cells

Zeng, K., Huang, M., Lyu, M.-A., Khoury, J. D., Ahmed, S., Patel, K. K., Dropulić, B., Reese‐Koc, J., Caimi, P. F., Sadeghi, T., et al. (2023) · Cells · doi:10.3390/cells12141880 · Cited by 9

Automation preserves product consistency and quality for the formulation, fill, and finish of T cell-based therapies

Park, M. S., Safford, M., Scheers, J., Hammill, L., Pleitez, D., Jerbi, T., Koudji, E. M., Yelity, S., Campion, S., Miller, M. M., et al. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.07.006 · Cited by 9

High-dimensional functional phenotyping of preclinical human CAR T cells using mass cytometry

Michelozzi, I. M., Sufi, J., Adejumo, T., Amrolia, P. J., Tape, C. J., & Giustacchini, A. (2022) · STAR Protocols · doi:10.1016/j.xpro.2022.101174 · Cited by 9

TCR-independent Activation in Presence of a Src-family Kinase Inhibitor Improves CAR-T Cell Product Attributes

Lamture, G., Baer, A., Fischer, J. W., Colon‐Moran, W., & Bhattarai, N. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000402 · Cited by 9

Redirecting tumor macrophage activity to fight cancer: Make room for the next era of anti-cancer drugs

Pucci, F., & Coussens, L. M. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.009 · Cited by 8

Release Assays and Potency Assays for CAR T-Cell Interventions

Dias, J., Cadiñanos-Garai, A., & Roddie, C. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-30040-0_8 · Cited by 10

A Quantitative Approach to Potency Testing for Chimeric Antigen Receptor-Encoding Lentiviral Vectors and Autologous CAR-T Cell Products, Using Flow Cytometry

Mata, J. J., Alserawan, L., España, C., Guijarro, C., López-Pecino, A., Calderón, H., Altuna, A., Pérez-Amill, L., Klein-González, N., de Larrea, C. F., et al. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030303 · Cited by 6

A Genetically Encoded Dark-to-Bright Biosensor for Visualisation of Granzyme-Mediated Cytotoxicity

Bednar, C., Kübel, S., Cordsmeier, A., Scholz, B., Menschikowski, H., & Ensser, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713589 · Cited by 7

Development of optimized cytotoxicity assays for assessing the antitumor potential of CAR-T cells

Norbert, M. E., Cuffel, A., Riou, G., Jean, L., Blondel, C., Déhayes, J., Bisson, A., Giverne, C., Brotin, É., Denoyelle, C., et al. (2023) · Journal of Immunological Methods · doi:10.1016/j.jim.2023.113603 · Cited by 7

Microwave biosensor for the detection of growth inhibition of human liver cancer cells at different concentrations of chemotherapeutic drug

Zhao, J.-M., Wang, Y., Shi, B.-W., Wang, Y.-X., Jiang, Y., Yang, G., Gao, X., & Qiang, T. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1398189 · Cited by 7

Preclinical In Vitro and In Vivo Models for Adoptive Cell Therapy of Cancer

Kaushik, G., Venkatesha, S. H., Verma, B., Vishwakarma, B. A., Zhang, A.-H., & Wesa, A. K. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000609 · Cited by 7

Coated recombinant target protein helps explore IL-1RAP CAR T-cell functionality in vitro

Rocha, M. N. D., Guiot, M., Nicod, C., Trad, R., Bouquet, L., Haderbache, R., Warda, W., Baurand, P.-E., Jouanneau, C., Dulieu, P., et al. (2022) · Immunologic Research · doi:10.1007/s12026-022-09348-y · Cited by 7

Celldetective: an AI-enhanced image analysis tool for unraveling dynamic cell interactionsPreprint

Torro, R., Díaz-Bello, B., Arawi, D. E., Dervanova, K., Ammer, L., Dupuy, F., Chames, P., Sengupta, K., & Limozin, L. (2025) · eLife · doi:10.7554/elife.105302.1 · Cited by 9

An Analysis of Monitoring Solutions for CAR T Cell Production

Shoshi, A., Xia, Y., Fieschi, A., Baumgarten, Y., Gaißler, A., Ackermann, T., Reimann, P., Mitschang, B., Weyrich, M., Bauernhansl, T., et al. (2025) · Healthcare Technology Letters · doi:10.1049/htl2.70012 · Cited by 6

A Digital Microfluidic Platform for the Microscale Production of Functional Immune Cell Therapies

Little, S. R., Rahbari, N., Hajiaghayi, M., Gholizadeh, F., Cloarec-Ung, F.-M., Philips, J., Sinha, H., Hirukawa, A., Knapp, D. J. H. F., Darlington, P. J., et al. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.4c06911 · Cited by 7

The potential of organoids in renal cell carcinoma research

Chen, Q., Sun, X., Li, Y., Yang, X., Yang, X., Xu, H., Cai, H., & Hu, J. (2024) · BMC Urology · doi:10.1186/s12894-024-01511-x · Cited by 6

Pemphigoid disease model systems for clinical translation

Tigges, M., Dräger, S., Piccini, I., Bieber, K., Vorobyev, A., Edelkamp, J., Bertolini, M., & Ludwig, R. J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1537428 · Cited by 6

EF1α, rather than CMV promoter, is suitable for luciferase tag expression in target cells for in vitro cytotoxicity assays of CAR-T cells

Hou, R., Zhang, Z., Li, H., He, W., Wang, X., Zhao, X., Li, S., Guan, Z., Liu, D., Zheng, J.-N., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101537 · Cited by 5

Coordinating oncogenesis and immune evasion: KPNA2, GOLM1, and TK1 as novel CAR T-cell targets in lung adenocarcinoma

Liu, W., Zou, H., Guo, L., Zhou, Z., Xie, Y., Guo, H., Wei, G., Zhang, K., Yin, H., Wei, S., et al. (2025) · European journal of medical research · doi:10.1186/s40001-025-02955-z · Cited by 5

The potential of microfluidic cell analysis in CAR T cell therapy manufacturing

Nikoniuk, A., Lilova, K., Thomas, M. R., & Szita, N. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1613836 · Cited by 4

Optimizing Ex Vivo CAR-T Cell-Mediated Cytotoxicity Assay through Multimodality Imaging

Foulke, J. G., Chen, L., Chang, H., McManus, C. E., Tian, F., & Gu, Z. (2024) · Cancers · doi:10.3390/cancers16142497 · Cited by 4

Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited

Rodríguez‐Lobato, L. G., Cardús, O., Mañé-Pujol, J., Battram, A. M., Vaqué-Salsench, S., Carpio, J., Pérez-Amill, L., Calderón, H., Martín-Antonio, B., Oliver‐Caldés, A., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-1313 · Cited by 4

Celldetective, an AI-enhanced image analysis tool for unraveling dynamic cell interactions

Torro, R., Díaz-Bello, B., Arawi, D. E., Dervanova, K., Ammer, L., Dupuy, F., Chames, P., Sengupta, K., & Limozin, L. (2026) · eLife · doi:10.7554/elife.105302.3 · Cited by 4

A synthetic cytotoxic T cell platform for rapidly prototyping TCR function

Sharma, G., Round, J. W., Teng, F., Ali, Z., May, C., Yung, E., & Holt, R. A. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00669-9 · Cited by 3

Establishment of CD1b-restricted immunity to lipid antigens in the pulmonary response to Mycobacterium tuberculosis infection

Harris, M. C., Gary, H. E., Cooper, S. K., Ackart, D. F., DiLisio, J. E., Basaraba, R. J., Cheng, T., Rhijn, I. V., Moody, D. B., & Podell, B. K. (2024) · Infection and Immunity · doi:10.1128/iai.00380-24 · Cited by 4

Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire

Rosenberger, L., Hansmann, L., Anastasopoulou, V., Wolf, S. P., Drousch, K., Moewes, C., Feng, X., Cao, G., Huang, J., Yew, P. Y., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011351 · Cited by 4

Chemoimmunotherapy Administration Protocol Design for the Treatment of Leukemia through Mathematical Modeling and In Silico Experimentation

Valle, P. A., Garrido, R., Salazar, Y., Coria, L. N., & Plata-Ante, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071396 · Cited by 4

A 3D in vitro assay to study combined immune cell infiltration and cytotoxicityPreprint

Crawford, A. J., Johnston, A. C., Du, W., Hanna, E. A., Schell, D., Wan, Z., Chen, T.-H., Wu, F., Ren, K., Lim, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.27.586980 · Cited by 4

Bio-functional hydrogel coated membranes to decrease T-cell exhaustion in manufacturing of CAR T-cells

Ruiz, A. L., Slaughter, E. D., Bomb, K., Swedzinski, S. L., LeValley, P. J., Yun, Z., McCoskey, J., Levine, K. B., Steen, J., Almasian, J., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1513148 · Cited by 4

GMP Manufacturing of Allogenic iPSC-NK Cells for Immunotherapy

Zong, H., & Wang, R. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-97297-3_15 · Cited by 3

Synthetic peptide hydrogels as a model of the bone marrow niche demonstrate efficacy of a combined CRISPR-CAR T-cell therapy for acute myeloid leukaemia

Doherty-Boyd, W. S., Tsimbouri, P. M., Jayawarna, V., Walker, M., Taqi, A. F., Mahon, N., Meek, R. M. D., Young, P. S., Miller, A. F., West, A. G., et al. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123803 · Cited by 3

CliCAR: A non-genetic CAR engineering strategy to empower NK cells for targeted cancer immunotherapy

Lim, S. Y., Kim, Y., Han, S., Kim, H., Ha, S.-J., Park, J., Yun, J., Chae, S., Won, Y., & Lim, K. S. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118691 · Cited by 3

Discovery of o-aminodiphenyl-based USP7 inhibitor for immune activation and antitumor response in colorectal cancer

Jia, G., Wang, Y., Zhou, W., Huang, X., & Song, Z. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115732 · Cited by 3

A novel immunocytokine promotes T cell– and cytokine-induced killer cell-mediated antitumor immunity via a non-MHC-restricted mechanism in glioblastoma

Zhang, X., Yang, N., Tang, X., Liu, N., Lu, Q., Zhang, Z., Xu, L., Jiang, L., Ge, H., Lu, H., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07321-5 · Cited by 3

Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups

Matsuzaka, Y., & Yashiro, R. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040268 · Cited by 3

Rapid In Vitro Cytotoxicity Evaluation of Jurkat Expressing Chimeric Antigen Receptor using Fluorescent Imaging

Subham, S., Jeppson, J. D., Gibbs, B. K., Babai, J., Alker, R., Godwin, A. K., & Akhavan, D. (2023) · Journal of Visualized Experiments · doi:10.3791/65560 · Cited by 3

A New Approach to In Vivo Transformation of Killer T Cells

Rodriguez, N., Hofmann, C., Yang, O. O., & Gelbart, W. M. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169369 · Cited by 4

Cellular Immunogenicity Assessments in CAR-T Cell Therapies: Current Insights and Future Directions

Masilamani, M., Balasubramanian, N., Mora, J. R., Park, A., & Jawa, V. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01129-3 · Cited by 2

Multi-parametric profiling of IL-7-augmented GD2.CART products in a phase 1 clinical trial

Schulenberg, S., Farrera-Sal, M., Loeser, M., Ehlen, L., Schlickeiser, S., Picht, S., Peter, L., Mai, M., Tat, C. L., Keye, J., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113680 · Cited by 2

Potency Assay Development: A Keystone for Clinical Use

Torggler, R., Margreiter, E., Marksteiner, R., & Thurner, M. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-30040-0_2 · Cited by 2

Immunotherapy in cancer: Where we are and what the future brings?

Kršek, A., Krpina, K., Miroslav, S., Detel, D., Batičić, L., & Tokmadžić, V. S. (2023) · Trends in Immunotherapy · doi:10.24294/ti.v7.i2.2186 · Cited by 2

Challenges and future perspectives for high-throughput chimeric antigen receptor T cell discovery

Butler, S. E., & Ackerman, M. E. (2024) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2024.103216 · Cited by 2

Current Role of CAR-T Therapy in Haematological Care

Jandová, M., Lánská, M., Šýkorová, A., Gregor, J., Rozsívalová, P., Beková, L., Ducháčová, Z. W., Radocha, J., Stacey, G., Měřička, P., et al. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-97297-3_16 · Cited by 2

FAM168B identified as a novel candidate target for chimeric antigen receptor T cell-based cancer therapy

Pramanik, S., Thaker, M., Inoue, N., Kim, P., Kutzner, A., Manavalan, A., Pramanik, G., & Heese, K. (2026) · Discover Oncology · doi:10.1007/s12672-025-03876-3 · Cited by 1

Genetically encoded biosensor of apoptosis and necrosis reveals the dynamics and biphasic cytotoxicity by Anti-EGFR CAR-T cells

Rather, A. A., Halikar, A. M., Sachdeva, R., Tiwari, S. K., & Santhoshkumar, T. R. (2026) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2026.118471 · Cited by 1

A 3D multi-compartment assembloid to study combined immune cell infiltration and cytotoxicity

Hanna, E. A., Crawford, A. J., Du, W., Johnston, A. C., Schell, D., Wan, Z., Chen, T.-H., Wu, F., Ren, K., Lim, Y., et al. (2026) · Cell Reports Methods · doi:10.1016/j.crmeth.2026.101307 · Cited by 7

Determinants of Chimeric Antigen Receptor (CAR) T Cell Success: In Vitro and In Vivo Preclinical Assessment

Sheng, M. K., & Murphy, W. J. (2026) · Cancers · doi:10.3390/cancers18091412 · Cited by 1

Droplet microfluidic profiling of NK cell cytotoxicity with machine learning-enabled target-cell death analysis

Ozcan, R., Vahedi, F., Namakian, S., Ashkar, A. A., & Didar, T. F. (2026) · Lab on a Chip · doi:10.1039/d6lc00301j · Cited by 1

Investigation of Conventional Radiation and Radionuclide at Ba‐Phalaborwa Roads, South Africa

Nemangwele, F., Nemakonde, P., & Mudau, T. (2025) · Applied and Environmental Soil Science · doi:10.1155/aess/6385437 · Cited by 1

Celldetective, an AI-enhanced image analysis tool for unraveling dynamic cell interactionsPreprint

Torro, R., Díaz-Bello, B., Arawi, D. E., Dervanova, K., Ammer, L., Dupuy, F., Chames, P., Sengupta, K., & Limozin, L. (2025) · eLife · doi:10.7554/elife.105302 · Cited by 3

Preclinical studies using CAR-T cells.

Kerbauy, L. N., de Godoy, J. A. P., Paiva, R. M. A., Kondo, A. T., Okamoto, O. K., & Bonamino, M. (2022) · JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY · doi:10.46765/2675-374x.2022v3n1p154

Comparison of CAR-T cell-mediated cytotoxicity assays with suspension tumor cells using high-throughput plate-based image cytometry method

Chan, L. L., Sun, Y., Chen, Y.-C., Hua, W., & Wu, S. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.210.supp.250.01

COMPARISON OF DIFFERENT CYTOTOXICITY ASSAYS AND IFN-γ PRODUCTION FOR CAR-T CELL PRODUCTS

McLaren, C., Bhise, G., Job, I., & Otegbeye, F. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.03.240 · Cited by 1

Comparison of chimeric antigen receptor‐T cell‐mediated cytotoxicity assays with suspension tumor cells using plate‐based image cytometry method

Sun, Y.-J., Chen, Y.-C., Hua, W.-K., Wu, S. C.-Y., & Chan, L. (2022) · Cytometry Part A · doi:10.1002/cyto.a.24673 · Cited by 3

Abstract 5326: Comparison of CAR-T cell-mediated cytotoxicity assays with suspension tumor cells using high-throughput plate-based image cytometry method

Chan, L. L., Sun, Y., Chen, Y.-C., Hua, W.-K., & Wu, S. C.-Y. (2023) · Cancer Research · doi:10.1158/1538-7445.am2023-5326

In vitro assays to evaluate CAR-T cell cytotoxicity

Cao, M., Carlson, R. D., Staudt, R. E., & Snook, A. E. (2023) · Methods in cell biology · doi:10.1016/bs.mcb.2023.05.009 · Cited by 4